Frontiers in Oncology (Dec 2023)
Corrigendum: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132
Abstract
No abstracts available.Keywords